CKPT241220C7500
- 0.05
- -0.06-54.55%
Checkpoint Therapeutics Newsroom
Lake Street Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Raises Target Price to $7
FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection
Analysts Offer Insights on Healthcare Companies: Checkpoint Therapeutics (CKPT) and Roche Holding AG (OtherRHHVF)
Trending Stocks Today | Sidus Space Shoots up 59.44% Pre-Market
Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval
FDA Approves Checkpoint Therapeutics' UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (Cosibelimab-ipdl)
Express News | FDA: Approval of Cosibelimab-Ipdl (Unloxcyt) Granted to Checkpoint Therapeutics
Express News | FDA Approves Cosibelimab-Ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma - Website
Express News | Trading Halt: Halted at 5:26:59 P.m. ET - Trading Halt: Halt News Pending
FDA Decision On Checkpoint Therapeutics' Cosibelimab Due On Dec.28 - Will Second Time Be The Charm?
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend
Checkpoint Therapeutics Analyst Ratings
Optimistic Buy Rating for Checkpoint Therapeutics Driven by Strong Financial Position and Strategic Collaborations
Checkpoint Therapeutics | 10-Q: Q3 2024 Earnings Report
Checkpoint Therapeutics | 8-K: Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Express News | Checkpoint Therapeutics Inc Qtrly Shr Loss $0.23
Express News | Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Press Release: Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
H.C. Wainwright Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Maintains Target Price $20